Skip to main content
Top

27-07-2017 | Colorectal cancer | Book chapter | Article

13. Liquid Biopsy in Colorectal Cancer

Authors: A. Galvano, M. Peeters, A. B. Di Stefano, M. Castiglia, Antonio Russo, MD, PhD

Publisher: Springer International Publishing

Abstract

Colorectal cancer (CRC) is the third most common cancer worldwide. Oncological CRC treatment is changing gradually replacing ancient drugs with the newest targeted agents (target therapy) and immunotherapy. The correct use of these molecular agents is based on a series of genetic evaluations able to predict treatment response. The tissue evaluation of these predictors is generally fully of serious limitations among which the invasiveness of the tissue biopsy procedure and its non-informative quality compared to the entire neoplastic mass. For these reasons, liquid biopsy could represent an ideal tool to obtain easily and quickly the necessary information to decide the best therapeutic strategy as well as to acquire data to monitor occurrence of resistance or to establish the recurrence probability.
Literature
1.
Rizzo S, et al. Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy? Cancer Treat Rev. 2010;36(Suppl 3):S56–61.CrossRefPubMed
2.
Wang JY, et al. Molecular detection of circulating tumor cells in the peripheral blood of patients with colorectal cancer using RT-PCR: significance of the prediction of postoperative metastasis. World J Surg. 2006;30:1007–13.CrossRefPubMed
3.
Uen YH, et al. Prognostic significance of multiple molecular markers for patients with stage II colorectal cancer undergoing curative resection. Ann Surg. 2007;246:1040–6.CrossRefPubMed
4.
Uen YH, et al. Persistent presence of postoperative circulating tumor cells is a poor prognostic factor for patients with stage I-III colorectal cancer after curative resection. Ann Surg Oncol. 2008;15:2120–8.CrossRefPubMed
5.
Lu CY, et al. Molecular detection of persistent postoperative circulating tumour cells in stages II and III colon cancer patients via multiple blood sampling: prognostic significance of detection for early relapse. Br J Cancer. 2011;104:1178–84.CrossRefPubMedPubMedCentral
6.
Iinuma H, et al. Clinical significance of circulating tumor cells, including cancer stem-like cells, in peripheral blood for recurrence and prognosis in patients with Dukes’ stage B and C colorectal cancer. J Clin Oncol. 2011;29:1547–55.CrossRefPubMed
7.
Lu CY, et al. Circulating tumor cells as a surrogate marker for determining clinical outcome to mFOLFOX chemotherapy in patients with stage III colon cancer. Br J Cancer. 2013;108:791–7.CrossRefPubMedPubMedCentral
8.
Yen LC, et al. Detection of KRAS oncogene in peripheral blood as a predictor of the response to cetuximab plus chemotherapy in patients with metastatic colorectal cancer. Clin Cancer Res. 2009;15:4508–13.CrossRefPubMed
9.
Barbazán J, et al. A multimarker panel for circulating tumor cells detection predicts patient outcome and therapy response in metastatic colorectal cancer. Int J Cancer. 2014;135:2633–43.CrossRefPubMed
10.
Jiao LR, et al. Unique localization of circulating tumor cells in patients with hepatic metastases. J Clin Oncol. 2009;27:6160–5.CrossRefPubMed
11.
Rahbari NN, et al. Compartmental differences of circulating tumor cells in colorectal cancer. Ann Surg Oncol. 2012;19:2195–202.CrossRefPubMed
12.
Matsusaka S, et al. Circulating tumor cells as a surrogate marker for determining response to chemotherapy in Japanese patients with metastatic colorectal cancer. Cancer Sci. 2011;102:1188–92.CrossRefPubMed
13.
de Albuquerque A, et al. Prognostic and predictive value of circulating tumor cell analysis in colorectal cancer patients. J Transl Med. 2012;10:222.CrossRefPubMedPubMedCentral
14.
Shi J, et al. Analysis of circulating tumor cells in colorectal cancer liver metastasis patients before and after cryosurgery. Cancer Biol Ther. 2016;17:935–42.CrossRefPubMedPubMedCentral
15.
Lalmahomed ZS, et al. Prognostic value of circulating tumour cells for early recurrence after resection of colorectal liver metastases. Br J Cancer. 2015;112:556–61.CrossRefPubMedPubMedCentral
16.
Groot Koerkamp B, Rahbari NN, Büchler MW, Koch M, Weitz J. Circulating tumor cells and prognosis of patients with resectable colorectal liver metastases or widespread metastatic colorectal cancer: a meta-analysis. Ann Surg Oncol. 2013;20:2156–65.CrossRefPubMed
17.
Bazan V, et al. Molecular detection of TP53, Ki-Ras and p16INK4A promoter methylation in plasma of patients with colorectal cancer and its association with prognosis. Results of a 3-year GOIM (Gruppo Oncologico dell’Italia Meridionale) prospective study. Ann Oncol. 2006;17(Suppl 7):vii84–90.PubMed
18.
Andreyev HJ, et al. Mutant K-ras2 in serum. Gut. 2003;52:915–6.CrossRefPubMedPubMedCentral
19.
Reinert T, et al. Analysis of circulating tumour DNA to monitor disease burden following colorectal cancer surgery. Gut. 2016;65:625–34.CrossRefPubMed
20.
Tie J, et al. Circulating tumor DNA (ctDNA) as a marker of recurrence risk in stage II colon cancer (CC). J Clin Oncol. 2014;32:5s.
21.
Thierry AR, et al. Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA. Nat Med. 2014;20:430–5.CrossRefPubMed
22.
Kidess E, et al. Mutation profiling of tumor DNA from plasma and tumor tissue of colorectal cancer patients with a novel, high-sensitivity multiplexed mutation detection platform. Oncotarget. 2015;6:2549–61.CrossRefPubMed
23.
Tie J, et al. Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer. Ann Oncol. 2015;26:1715–22.CrossRefPubMedPubMedCentral
24.
Spindler KL, Pallisgaard N, Vogelius I, Jakobsen A. Quantitative cell-free DNA, KRAS, and BRAF mutations in plasma from patients with metastatic colorectal cancer during treatment with cetuximab and irinotecan. Clin Cancer Res. 2012;18:1177–85.CrossRefPubMed
25.
Bardelli A, et al. Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. Cancer Discov. 2013;3:658–73.CrossRefPubMedPubMedCentral
26.
Morelli MP, et al. Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment. Ann Oncol. 2015;26:731–6.CrossRefPubMedPubMedCentral
27.
Spindler KL, Pallisgaard N, Andersen RF, Jakobsen A. Changes in mutational status during third-line treatment for metastatic colorectal cancer--results of consecutive measurement of cell free DNA, KRAS and BRAF in the plasma. Int J Cancer. 2014a;135:2215–22.CrossRefPubMed
28.
Spindler KL, et al. Cell-free DNA in healthy individuals, noncancerous disease and strong prognostic value in colorectal cancer. Int J Cancer. 2014b;135:2984–91.CrossRefPubMed
29.
El Messaoudi S, et al. Circulating DNA as a strong multimarker prognostic tool for metastatic colorectal cancer patient management care. Clin Cancer Res. 2016;22:3067–77.CrossRefPubMed
30.
Spindler KL, et al. Clinical utility of KRAS status in circulating plasma DNA compared to archival tumour tissue from patients with metastatic colorectal cancer treated with anti-epidermal growth factor receptor therapy. Eur J Cancer. 2015;51:2678–85.CrossRefPubMed
31.
Perrone F, et al. Circulating free DNA in a screening program for early colorectal cancer detection. Tumori. 2014;100:115–21.PubMed
32.
Parolini I, et al. Microenvironmental pH is a key factor for exosome traffic in tumor cells. J Biol Chem. 2009;284:34211–22.CrossRefPubMedPubMedCentral
33.
Ge Q, et al. miRNA in plasma exosome is stable under different storage conditions. Molecules. 2014;19:1568–75.CrossRefPubMed
34.
Zhou W, et al. Cancer-secreted miR-105 destroys vascular endothelial barriers to promote metastasis. Cancer Cell. 2014;25:501–15.CrossRefPubMedPubMedCentral
35.
Kucharzewska P, et al. Exosomes reflect the hypoxic status of glioma cells and mediate hypoxia-dependent activation of vascular cells during tumor development. Proc Natl Acad Sci U S A. 2013;110:7312–7.CrossRefPubMedPubMedCentral
36.
Ekström EJ, et al. WNT5A induces release of exosomes containing pro-angiogenic and immunosuppressive factors from malignant melanoma cells. Mol Cancer. 2014;13:88.CrossRefPubMedPubMedCentral
37.
Skog J, et al. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol. 2008;10:1470–6.CrossRefPubMedPubMedCentral
38.
Ji H, et al. Proteome profiling of exosomes derived from human primary and metastatic colorectal cancer cells reveal differential expression of key metastatic factors and signal transduction components. Proteomics. 2013;13:1672–86.CrossRefPubMed
39.
Al-Nedawi K, et al. Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells. Nat Cell Biol. 2008;10:619–24.CrossRefPubMed
40.
Lokody I. Genetics: exosomally derived miR-105 destroys tight junctions. Nat Rev Cancer. 2014;14:386–7.CrossRefPubMed
41.
Chowdhury R, et al. Cancer exosomes trigger mesenchymal stem cell differentiation into pro-angiogenic and pro-invasive myofibroblasts. Oncotarget. 2015;6:715–31.CrossRefPubMed
42.
Maitland NJ. Carcinoma-derived exosomes modify microenvironment. Oncotarget. 2015;6:1344–5.CrossRefPubMedPubMedCentral
43.
Tauro BJ, et al. Two distinct populations of exosomes are released from LIM1863 colon carcinoma cell-derived organoids. Mol Cell Proteomics. 2013;12:587–98.CrossRefPubMed
44.
Yoshioka Y, et al. Ultra-sensitive liquid biopsy of circulating extracellular vesicles using ExoScreen. Nat Commun. 2014;5:3591.CrossRefPubMedPubMedCentral
45.
Gallo A, Tandon M, Alevizos I, Illei GG. The majority of microRNAs detectable in serum and saliva is concentrated in exosomes. PLoS One. 2012;7:e30679.CrossRefPubMedPubMedCentral
46.
Caruso S, et al. MicroRNAs in colorectal cancer stem cells: new regulators of cancer stemness? Oncogenesis. 2012;1:e32.CrossRefPubMedPubMedCentral
47.
Corsini LR, et al. The role of microRNAs in cancer: diagnostic and prognostic biomarkers and targets of therapies. Expert Opin Ther Targets. 2012;16(Suppl 2):S103–9.CrossRefPubMed
48.
Ogata-Kawata H, et al. Circulating exosomal microRNAs as biomarkers of colon cancer. PLoS One. 2014;9:e92921.CrossRefPubMedPubMedCentral
49.
Chiba M, Kimura M, Asari S. Exosomes secreted from human colorectal cancer cell lines contain mRNAs, microRNAs and natural antisense RNAs, that can transfer into the human hepatoma HepG2 and lung cancer A549 cell lines. Oncol Rep. 2012;28:1551–8.CrossRefPubMedPubMedCentral
50.
Senfter D, et al. Loss of miR-200 family in 5-fluorouracil resistant colon cancer drives lymphendothelial invasiveness in vitro. Hum Mol Genet. 2015;24:3689–98.PubMed